Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain

Abstract

Objective:

The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (≥5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain.

Methods:

The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year.

Results:

Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than €30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis.

Conclusions:

For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.

Keywords::

• Cardiovascular disease
• Cost-effectiveness
• Rosuvastatin
• Atorvastatin

Transparency

Declaration of funding

This study was supported by AstraZeneca Spain.

Declaration of financial/other relationships

V.B., J.M.L. and A.S. have received consulting and presentation fees from Pfizer and AstraZeneca. M.B. is a consultant for Oblikue Consulting. M.C. and C.Á. are employees of AstraZeneca Spain.

Acknowledgments

Assistance with translation and editing of the original manuscript from Spanish into English was provided by Liz Anfield, Prime Medica Ltd, Knutsford, Cheshire, UK, funded by AstraZeneca.

Responsibility for opinions, conclusions, and interpretation of data lies with the authors. Max Brosa wrote the first draft of the manuscript, and all authors have contributed to each stage of the manuscript during its development and approved the final version of the manuscript for submission.